https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-05-01 / J. Immunother. 2008 May;31(4):345-58
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-05-01 / J. Immunother. 2008 May;31(4):345-582008-05-01 00:00:002019-02-15 09:19:30Mechanisms involved in radiation enhancement of intratumoral dendritic cell therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-05-01 / J. Immunother. 2008 May;31(4):402-12
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-05-01 / J. Immunother. 2008 May;31(4):402-122008-05-01 00:00:002019-02-15 09:19:31Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-05-01 / Rev Recent Clin Trials 2008 May;3(2):121-5
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-05-01 / Rev Recent Clin Trials 2008 May;3(2):121-52008-05-01 00:00:002019-02-15 09:23:43Immunotherapy of pancreatic carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-04-24 / Vaccine 2008 Jun;26(27-28):3540-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-04-24 / Vaccine 2008 Jun;26(27-28):3540-92008-04-24 00:00:002019-02-15 08:49:58Therapeutic vaccination with dendritic cells pulsed with tumor-derived Hsp70 and a COX-2 inhibitor induces protective immunity against B16 melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-04-21 / J. Leukoc. Biol. 2008 Jul;84(1):319-25
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-04-21 / J. Leukoc. Biol. 2008 Jul;84(1):319-252008-04-21 00:00:002019-02-15 08:37:26Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-04-15 / Int. J. Cancer 2008 Apr;122(8):1794-802
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-04-15 / Int. J. Cancer 2008 Apr;122(8):1794-8022008-04-15 00:00:002019-02-15 08:59:45Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-04-09 / Trends Mol Med 2008 May;14(5):228-35
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-04-09 / Trends Mol Med 2008 May;14(5):228-352008-04-09 00:00:002019-02-15 08:46:53Cell- and peptide-based immunotherapeutic approaches for glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-04-01 / Int. J. Oncol. 2008 Apr;32(4):851-60
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-04-01 / Int. J. Oncol. 2008 Apr;32(4):851-602008-04-01 00:00:002019-02-15 08:35:01Hyperthermia switches glucose depletion-induced necrosis to apoptosis in A549 lung adenocarcinoma cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-04-01 / Cancer Biother. Radiopharm. 2008 Apr;23(2):214-21
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-04-01 / Cancer Biother. Radiopharm. 2008 Apr;23(2):214-212008-04-01 00:00:002019-02-15 09:19:30Lack of elevation of serum S100B in patients with metastatic melanoma as a predictor of outcome after induction with an autologous vaccine of proliferating tumor cells and dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-04-01 / Immunol. Rev. 2008 Apr;222:242-55
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-04-01 / Immunol. Rev. 2008 Apr;222:242-552008-04-01 00:00:002019-02-15 09:19:32Cancer vaccines for established cancer: how to make them better?
